Bradykinin/bradykinin 1 Receptor Promotes Brain Microvascular Endothelial Cell Permeability and Proinflammatory Cytokine Release by Downregulating Wnt3a

Overview

Journal J Biochem Mol Toxicol

Publisher Wiley

Specialties Biochemistry
Molecular Biology
Toxicology

Date 2022 Sep 16

PMID 36111657

Authors

Linqiang Huang

Mengting Liu

Wenqiang Jiang

Hongguang Ding

Yongli Han

Miaoyun Wen

Ya Li

Xiaoyu Liu

Hongke Zeng

Affiliations

Soon will be listed here.

Abstract

Stroke is a life-threatening disease with limited therapeutic options. Damage to the blood-brain barrier (BBB) is the key pathological feature of ischemic stroke. This study explored the role of the bradykinin (BK)/bradykinin 1 receptor (B1R) and its mechanism of action in the BBB. Human brain microvascular endothelial cells (BMECs) were used to test for cellular responses to BK by using the Cell Counting Kit-8 assay, 5-ethynyl-2'-deoxyuridine staining, enzyme-linked immunosorbent assay, flow cytometry, immunofluorescence, cellular permeability assays, and western blotting to evaluate cell viability, cytokine production, and reactive oxygen species (ROS) levels in vitro. A BBB induced by middle cerebral artery occlusion was used to evaluate BBB injuries, and the role played by BK/B1R in ischemic/reperfusion (I/R) was explored in a rat model. Results showed that BK reduced the viability of BMECs and increased the levels of proinflammatory cytokines (interleukin 6 [IL-6], IL-18, and monocyte chemoattractant protein-1) and ROS. Additionally, cellular permeability was increased by BK treatment, and the expression of tight junction proteins (claudin-5 and occludin) was decreased. Interestingly, Wnt3a expression was inhibited by BK and exogenous Wnt3a restored the effects of BK on BMECs. In an in vivo I/R rat model, knockdown of B1R significantly decreased infarct volume and inflammation in I/R rats. Our results suggest that BK might be a key inducer of BBB injury and B1R knockdown might provide a beneficial effect by upregulating Wnt3a.

Citing Articles

Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications.

Ebrahimi M, Ahmadieh H, Kanavi M, Safi S, Alipour-Parsa S, Advani S Front Med (Lausanne). 2025; 11:1497750.

PMID: 39845838 PMC: 11750824. DOI: 10.3389/fmed.2024.1497750.

Glutathione in HIV-Associated Neurocognitive Disorders.

Erdos T, Masuda M, Venketaraman V Curr Issues Mol Biol. 2024; 46(6):5530-5549.

PMID: 38921002 PMC: 11202908. DOI: 10.3390/cimb46060330.

Bradykinin-bradykinin receptor (B1R) signalling is involved in the blood-brain barrier disruption in moyamoya disease.

Wang H, Sun W, Li F, Jiang P, Wang L, Zhou N J Cell Mol Med. 2023; 27(24):4069-4079.

PMID: 37818853 PMC: 10746938. DOI: 10.1111/jcmm.17989.

Multiple Sclerosis: Inflammatory and Neuroglial Aspects.

Papiri G, DAndreamatteo G, Cacchio G, Alia S, Silvestrini M, Paci C Curr Issues Mol Biol. 2023; 45(2):1443-1470.

PMID: 36826039 PMC: 9954863. DOI: 10.3390/cimb45020094.

Bradykinin/bradykinin 1 receptor promotes brain microvascular endothelial cell permeability and proinflammatory cytokine release by downregulating Wnt3a.

Huang L, Liu M, Jiang W, Ding H, Han Y, Wen M J Biochem Mol Toxicol. 2022; 36(12):e23213.

PMID: 36111657 PMC: 10078380. DOI: 10.1002/jbt.23213.

References

Mugisho O, Robilliard L, Nicholson L, Graham E, OCarroll S . Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells. Cell Biol Int. 2019; 44(1):343-351. DOI: 10.1002/cbin.11232. View

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

Zhang J, Zhang J, Qi C, Yang P, Chen X, Liu Y . Activation of Wnt3α/β-catenin signal pathway attenuates apoptosis of the cerebral microvascular endothelial cells induced by oxygen-glucose deprivation. Biochem Biophys Res Commun. 2017; 490(2):71-77. DOI: 10.1016/j.bbrc.2017.03.130. View

Huang L, Liu M, Jiang W, Ding H, Han Y, Wen M . Bradykinin/bradykinin 1 receptor promotes brain microvascular endothelial cell permeability and proinflammatory cytokine release by downregulating Wnt3a. J Biochem Mol Toxicol. 2022; 36(12):e23213. PMC: 10078380. DOI: 10.1002/jbt.23213. View

Campbell B, De Silva D, Macleod M, Coutts S, Schwamm L, Davis S . Ischaemic stroke. Nat Rev Dis Primers. 2019; 5(1):70. DOI: 10.1038/s41572-019-0118-8. View

Kuriakose D, Xiao Z . Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci. 2020; 21(20). PMC: 7589849. DOI: 10.3390/ijms21207609. View

Lasek-Bal A, Kokot A, Gendosz de Carrillo D, Student S, Pawletko K, Krzan A . Plasma Levels of Occludin and Claudin-5 in Acute Stroke Are Correlated with the Type and Location of Stroke but Not with the Neurological State of Patients-Preliminary Data. Brain Sci. 2020; 10(11). PMC: 7695327. DOI: 10.3390/brainsci10110831. View

Helms H, Abbott N, Burek M, Cecchelli R, Couraud P, Deli M . In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016; 36(5):862-90. PMC: 4853841. DOI: 10.1177/0271678X16630991. View

Shahriyary L, Riazi G, Lornejad M, Ghezlou M, Bigdeli B, Delavari B . Effect of glycated insulin on the blood-brain barrier permeability: An in vitro study. Arch Biochem Biophys. 2018; 647:54-66. DOI: 10.1016/j.abb.2018.02.004. View

10.

Acosta S, Lee J, Nguyen H, Kaneko Y, Borlongan C . Endothelial Progenitor Cells Modulate Inflammation-Associated Stroke Vasculome. Stem Cell Rev Rep. 2019; 15(2):256-275. PMC: 6441406. DOI: 10.1007/s12015-019-9873-x. View

11.

Su J, Cui M, Tang Y, Zhou H, Liu L, Dong Q . Blockade of bradykinin B2 receptor more effectively reduces postischemic blood-brain barrier disruption and cytokines release than B1 receptor inhibition. Biochem Biophys Res Commun. 2009; 388(2):205-11. DOI: 10.1016/j.bbrc.2009.07.135. View

12.

Laksitorini M, Yathindranath V, Xiong W, Hombach-Klonisch S, Miller D . Modulation of Wnt/β-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells. Sci Rep. 2019; 9(1):19718. PMC: 6928218. DOI: 10.1038/s41598-019-56075-w. View

13.

Hawkins B, Davis T . The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57(2):173-85. DOI: 10.1124/pr.57.2.4. View

14.

Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla C . Wnt/beta-catenin signaling controls development of the blood-brain barrier. J Cell Biol. 2008; 183(3):409-17. PMC: 2575783. DOI: 10.1083/jcb.200806024. View

15.

Zhao Y, Gibb S, Zhao J, Moore A, Hylin M, Menge T . Wnt3a, a Protein Secreted by Mesenchymal Stem Cells Is Neuroprotective and Promotes Neurocognitive Recovery Following Traumatic Brain Injury. Stem Cells. 2016; 34(5):1263-72. DOI: 10.1002/stem.2310. View

16.

Zhang D, Lu Z, Man J, Cui K, Fu X, Yu L . Wnt-3a alleviates neuroinflammation after ischemic stroke by modulating the responses of microglia/macrophages and astrocytes. Int Immunopharmacol. 2019; 75:105760. DOI: 10.1016/j.intimp.2019.105760. View

17.

Agundez J, Jimenez-Jimenez F, Alonso-Navarro H, Garcia-Martin E . Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. Front Cell Neurosci. 2014; 8:335. PMC: 4201098. DOI: 10.3389/fncel.2014.00335. View

18.

Raslan F, Schwarz T, Meuth S, Austinat M, Bader M, Renne T . Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab. 2010; 30(8):1477-86. PMC: 2949241. DOI: 10.1038/jcbfm.2010.28. View

19.

Matei N, Camara J, McBride D, Camara R, Xu N, Tang J . Intranasal wnt3a Attenuates Neuronal Apoptosis through Frz1/PIWIL1a/FOXM1 Pathway in MCAO Rats. J Neurosci. 2018; 38(30):6787-6801. PMC: 6067074. DOI: 10.1523/JNEUROSCI.2352-17.2018. View

20.

Bartus R, Elliott P, Hayward N, Dean R, McEwen E, Fisher S . Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology. 1996; 33(1-3):270-8. DOI: 10.1016/0162-3109(96)00070-7. View